Chronic pain and therapeutic opportunities, exploring CNTX-6970’s case study and the role of Big Data in drug discovery and development

On Mar 19, 2018

SMi Group reports: The chronic pain epidemic today affects thousands of patients worldwide. It is now a point of concern for the pharmaceutical industry, for the healthcare industry and gains substantial media coverage. SMi’s 18th annual Pain Therapeutics Conference will be digging deep into new research and studies related to therapeutic opportunities for chronic pain.

[CNTX-6970 is a novel, potent and selective CCR2 antagonist with a unique analgesic profile. Recent studies have shown a close link between chronic pain and the immune system. CNTX-6970 capitalizes on this connection by taking a novel “neuro-immune” approach. CNTX-6970 is predicted to be well suited to treat chronic painful inflammatory conditions such as osteoarthritis, and current studies show the treatment is safe and well tolerated with demonstrated pharmacologic activity. CNTX-6970 has successfully completed Phase 1 single-ascending-dose studies.]*

Randall Stevens, Chief Medical Officer at Centrexion Therapeutics will update participants of the Pain Therapeutics Conference this May on the progress of CNTX-6970 study (Day 2) with the focus on:

Mechanism of action
Unique analgesic signature in preclinical models
Using Big Data to identify clinical development targets
Findings from Phase 1 clinical studies and next steps

And Randall’s colleague Kerrie Brady, Chief Business Officer, Executive VP Strategy, at Centrexion Therapeutics will look into the topic of Big Data for Big Decisions (Day 2) focusing on such questions as:

How to best develop a portfolio of novel non-opioid products for pain?
Integration of human expertise and artificial intelligence
Using metadata to qualify big data output
Can Big Data increase technical success for novel pain drug development?

Read more on these presentations and view full programme of the Pain Therapeutics conference website at www.pain-therapeutics.co.uk/pharmajournPR

Twitter – @SMIpharm & #smipaintherapeutics
LinkedIn – SMi Pharma

CONTACT:
+44 (0)20 7827 6000
events@smi-online.co.uk

————————————————————————————————————-

Pain Therapeutics Conference | 21 – 22 May 2018 | London, UK www.pain-therapeutics.co.uk/pharmajournPR

————————————————————————————————————-

* centrexion.com/wp-content/uploads/2017/07/Centrexion_Pipeline_Updates.pdf